- Home
- A-Z Publications
- CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders)
- Previous Issues
- Volume 16, Issue 6, 2017
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) - Volume 16, Issue 6, 2017
Volume 16, Issue 6, 2017
-
-
Exercise Induced Neuroplasticity to Enhance Therapeutic Outcomes of Cognitive Remediation in Schizophrenia: Analyzing the Role of Brai nderived Neurotrophic Factor
Authors: Carlos Campos, Nuno B.F Rocha, Eduardo Lattari, Antonio E. Nardi and Sergio MachadoBackground: Cognitive impairment is a major manifestation of schizophrenia and a crucial treatment target as these deficits are closely related to patients' functional outcomes. Cognitive remediation is the gold-standard practice to address cognitive deficits in schizophrenia. There is clear evidence stating that cognitive remediation improves cognitive function and promotes structural neuroplastic changes in patients with s Read More
-
-
-
Caffeine; the Forgotten Potential for Parkinson's Disease
Authors: Ahmed Negida, Mohamed Elfil, Attia Attia, Eslam Farahat, Mohamed Gabr, Ahmed Essam, Doaa Attia and Hussein AhmedBackground: Parkinson's disease (PD) is the second most common neurological disorder characterized by loss of dopaminergic fibers in the basal ganglia and presence of Lewy bodies. Method and Results: The literature suggests that caffeine plays multiple roles in PD. Epidemiological studies showed that caffeine intake was associated with less risk of developing PD, especially in genetically susceptible patients. On the level of Read More
-
-
-
GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update
More LessBackground: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs. Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may Read More
-
-
-
Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
Background: Worldwide, at least 2.8 million people die each year as a result of being overweight or obese. Obesity leads to metabolic syndrome, a pathological condition characterized by adverse metabolic effects on blood pressure, cholesterol, triglycerides and insulin resistance. Population- based investigations have suggested that obesity and metabolic syndrome may be associated with poorer cognitive performance. Meth Read More
-
-
-
Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease
Background: A considerable amount of data suggests the age-related impairments of mitochondrial functions in the development of sporadic forms of neurodegenerative pathologies. Mitochondria and the phenomenon of mitochondrial permeability transition (MPT), which marks the point of no return in cell death cascades, have special value in this regard. It is important that the vulnerability to MPT-inducing factors is increased Read More
-
-
-
Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
Authors: Qiong Luo, Zhen Ren, Linlin Zhu, Yiye Shao, Yangmei Xie, Yonghao Feng, Bing Li and Yinghui ChenBackground: Status epilepticus (SE), is characterized by high mortality and morbidity, which can cause neuronal injury, neuronal death and alteration of neuronal networks, Recently, inflammation was shown to play a significant role in SE pathogenesis. And miRNA-146a has been shown to be involved in inflammation and to inhibit inflammatory cytokines through NF-ΚB pathway. In our study, we investigated the relationsh Read More
-
-
-
Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats
Background: Epilepsy is a central disorder associated with neuronal damage and brain hypometabolism. It has been reported that antidepressant drugs show anticonvulsant and neuroprotective effects in different animal models of seizures and epilepsy. Aims: The purpose of this study was to investigate the eventual short-term brain impairment induced by a single low convulsant dose of the potassium channel blocker 4-amino Read More
-
-
-
Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease
Authors: Stefania Brotini, Carlo Schievano and Leonello GuidiBackground: Parkinson's disease (PD) is the subject of intense efforts to develop strategies that slow down or stop disease progression and disability. Substantial evidence points to a prominent role for neuroinflammation in the underlying dopaminergic cell death. Ultramicronized palmitoylethanolamide (um-PEA) is well-known for its ability to promote the resolution of neuroinflammation and exert neuroprotection. Read More
-
-
-
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
Background: In April 2015, the US Food and Drug Administration approved the first generic glatiramer acetate, Glatopa® (M356), as fully substitutable for Copaxone® 20 mg/mL for relapsing forms of multiple sclerosis (MS). This approval was accomplished through an Abbreviated New Drug Application that demonstrated equivalence to Copaxone. Method: This article will provide an overview of the methods used to esta Read More
-
-
-
The Effect of Pyrroloquinoline Quinone on Apoptosis and Autopha gy in Traumatic Brain Injury
Authors: Pengju Zhang, Yongqi Ye, Yuhang Qian, Baoxin Yin, Jianmei Zhao, Shunxin Zhu, Li Zhang and Meijuan YanBackground: Pyrroloquinoline quinone is an anionic, water-soluble compound with antioxidant characteristic. The role of pyrroloquinoline quinone in pharmacology and nutrition has attracted wide attention of researchers. Although a few experiments have confirmed that pyrroloquinoline quinone plays an obvious effective role in neuroprotection. There are few reports about the effect of pyrroloquinoline quinone on traumatic brain Read More
-
Volumes & issues
-
Volume 24 (2025)
-
Volume 23 (2024)
-
Volume 22 (2023)
-
Volume 21 (2022)
-
Volume 20 (2021)
-
Volume 19 (2020)
-
Volume 18 (2019)
-
Volume 17 (2018)
-
Volume 16 (2017)
-
Volume 15 (2016)
-
Volume 14 (2015)
-
Volume 13 (2014)
-
Volume 12 (2013)
-
Volume 11 (2012)
-
Volume 10 (2011)
-
Volume 9 (2010)
-
Volume 8 (2009)
-
Volume 7 (2008)
-
Volume 6 (2007)
-
Volume 5 (2006)
Most Read This Month
Article
content/journals/cnsnddt
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
Authors: Dafin F. Muresanu, Alexandru V. Ciurea, Radu M. Gorgan, Eva Gheorghita, Stefan I. Florian, Horatiu Stan, Alin Blaga, Nicolai Ianovici, Stefan M. Iencean, Dana Turliuc, Horia B. Davidescu, Cornel Mihalache, Felix M. Brehar, Anca . S. Mihaescu, Dinu C. Mardare, Aurelian Anghelescu, Carmen Chiparus, Magdalena Lapadat, Viorel Pruna, Dumitru Mohan, Constantin Costea, Daniel Costea, Claudiu Palade, Narcisa Bucur, Jesus Figueroa and Anton Alvarez
-
-
-
- More Less